Leman Bio Achieves 100% CR in Multiple Patients with 1‰ Dose Metabolically Enhanced CAR-T Therapy, Files IPO Prospectus

Note: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs and does not recommend treatment plans (if involved), nor does it represent the platform's position.Any article reprinted needs to be authorized.

Recently, XtalPi (2228.HK) Incubated company Leman Biotech Co., Ltd. delivered a speech at the 44th J.P. Morgan Healthcare Conference and presented the latest results of its Investigator-Initiated Trial (IIT) on ultra-low-dose CAR-T therapy to global investors.With the R&D support from XtalPi,Leman Biotech Co., Ltd has developed multiple R&D pipelines based on its AI + Immune Metabolic Reprogramming platform. Among them is the metabolically enhanced CD19 CAR-T therapy,At an ultra-low dose of only one-thousandth (1‰) of the conventional CAR-T treatment dose, complete remission (100% CR) was achieved in multiple systemic lupus erythematosus patients, demonstrating a new possibility for future "outpatient" CAR-T therapy.At the same time，This therapy has helpedDozens of patients with relapsed/refractory leukemia/lymphoma achieved CR,And withMoreClinical trials in the field of solid tumors are currently being conducted or are about to be launched. These advancements once again demonstrate the outstanding capability of XtalPi's R&D platform in empowering disruptive technologies and accelerating clinical translation.

Under the investment incubation and R&D empowerment of XtalPi, Leman Biotech focuses on innovative tumor immunotherapy.Development of therapeutic drug pipelines, continuously upgrading its uniqueMETA 10Metabolic Reprogramming Technology Platform. The two companies have also collaborated to developMETA 10-AI The platform, combining XtalPi's AI algorithms with high-throughput screening experiments, optimized the design of core metabolic enhancers used in metabolism-enhanced CAR-T therapy, making themAchieving Hundreds of Times Increase in Affinity; The team also developed an "ultra-high-definition microscope" for AI training,Antibodies that precisely identify the subtle characteristic differences of only one amino acid between tumor markers and healthy markers significantly enhance the affinity, specificity, and immunological activity of CAR-T therapy in receptor binding., while "efficiently killing enemies," avoid collateral damage, minimize toxic side effects as much as possible, and deliver superior efficacy and safety. The relevant results have currently been patented in China and applied to the development of metabolic-enhanced CAR-T pipelines for solid tumor targets, significantly improving the anti-exhaustion capability of CAR-T cells within the immunosuppressive microenvironment of solid tumors.

AI + Immune Metabolism Reprogramming,

Breaking the Bottleneck in CAR-T Therapy

According to estimates by Grand View Research, the global CAR-T therapy market size was $4.65 billion in 2024 and is expected to reach $15.97 billion by 2030, with a compound annual growth rate (CAGR) of 22.2%. Although CAR-T therapy has achieved certain successes in the field of hematologic tumors, it still faces three major challenges: high recurrence rates, limited response in solid tumors, and high costs. The root cause lies in T cells' tendency to enter a state of "terminal exhaustion" during continuous anti-tumor processes, losing their ability to proliferate and kill, and showing no response to immune checkpoint inhibitors such as PD-1/PD-L1.

Leman Biotech, an innovative company incubated and invested in by XtalPi in 2022, has its founding team originating from the globally renowned engineering university, École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. Through in-depth research and development collaboration with XtalPi, Leman Biotech has developed its proprietary...META 10 withMETA 10-AI Two Major AI+Metabolic Reprogramming Technology Platform, achieving precise regulation of exhausted T cell metabolism, thereby significantly enhancing their proliferation capacity, cytotoxic activity, and immune memory function,Achieve a higher clinical response rate and better safety with a lower dose, lower cost, and faster preparation process.To drive patients to achieve complete remission and provide them with a more ideal choice for cell therapy.

Hematological Tumors and Autoimmune Diseases

Clinical Dual Breakthrough

With the support of XtalPi, the metabolically enhanced CD19 CAR-T therapy developed by Leman Biotech has demonstrated breakthrough therapeutic potential in autoimmune diseases and hematological malignancies. In 2025, Leman Biotech initiated an IIT clinical study targeting Systemic Lupus Erythematosus (SLE), achieving significant progress. This therapy, with only...ForA very low dose of one-thousandth (1‰) of the conventional CAR-T treatment dose，Successfully Achieved Drug-Free Complete Remission in Multiple Patients with Moderate to Severe SLE Without Lymphodepletion Preconditioning, Without Interrupting Original Immunosuppressive Medications, and with Significantly Shortened Hospitalization（100% CR）。Based on favorable safety data, the metabolically enhanced CD19 CAR-T therapy is expected to support an outpatient administration model, providing a more convenient and safer "immune reset" treatment paradigm for autoimmune diseases.

In the IIT clinical trials in the field of malignant hematological tumors，Metabolism-enhanced CD19 CAR-T therapy also showed impressive results.The first group of over 20 patients with relapsed/refractory leukemia/lymphoma also all achieved complete remission (100% CR) and were successfully discharged.In addition, this study successfully covered pediatric patients and patients with chronic lymphoma who had poor responses to traditional CAR-T therapy. The first enrolled pediatric patient and the first chronic lymphoma patient both achieved CR. In terms of safety, the patients’ vital signs remained stable and controllable during the treatment process, with no severe side effects commonly associated with CAR-T treatment, such as serious cytokine release syndrome or severe neurotoxicity, being observed.

Platform Technology,

Reshaping the Economics and Accessibility of Cell Therapy

Leman Biotech Co., Ltd.'s Relevant Clinical Research Awarded the Highest Prize of "Honorary Award" in the 2025 China Disruptive Technology Innovation Competition, and Received Funding from the Key Special Project of China's National Key R&D Plan for Disruptive Technology Innovation. This advancement is expected to change the current situation of CAR-T therapy being priced at "a million yuan per injection," having a low response rate, and significant toxic side effects. It will also utilize small automated equipment to achieve rapid production and further cost reduction, laying the foundation for the market launch of a new generation of safe, efficient, and "affordable" CAR-T therapies, and even their inclusion in health insurance.Promote Cell Therapy: From "Treatment" to "Cure," and from "Centralized Production" to "Outpatient Preparation"

In addition to hematological tumors and autoimmune diseases, Leman Biotech is expanding the META 10 platform to areas such as solid tumors.Metabolism-Enhanced Cell Therapy for Solid Tumor Indications such as Cervical Cancer, Liver Cancer, and Bile Duct Cancer has Entered the IIT Clinical Research StagePatient recruitment and treatment enrollment are currently underway. The IL-10 CAR-T therapy targeting EGFR vIII-positive glioblastoma and GPC3-positive hepatocellular carcinoma has entered the IIT clinical preparation stage, with the IIT clinical study expected to commence in the first quarter of 2026.

Notably, Leman Biotech's META 10 technology platform is highly compatible, applicable not only to autologous CAR-T but also extendable to various cell therapy modalities such as in vivo CAR-T, TCR-T, and TILs. It has the potential to provide partners with "plug-and-play" solutions. The flexibility and scalability of this technology make it a "universal engine" in the field of cell therapy, capable of rapidly advancing the upgrading and expansion of therapeutic pipelines.

The rapid development of Leman Biotech and its series of breakthrough achievements in CAR-T therapy serve as another strong testament to the successful incubation capabilities of XtalPi's "AI + Robotics" empowerment platform. XtalPi not only provided crucial financial support to Leman Biotech but also deeply participated in the development and continuous optimization of Leman’s core platforms (META 10, META 10-AI) through its industry-leading AI drug discovery platform, accelerating the progress of its pipeline development. Leman Biotech's groundbreaking clinical results in hematological tumors and autoimmune diseases, along with its rapid advancements in solid tumors, demonstrate significant clinical value and commercial potential.XtalPi will continue to empower frontier companies like Leman Biotech, incubate more disruptive therapies, and lead the source innovation in the biopharmaceutical industry.

Source of the article:Leman